BillionToOneBLLN +2.04%13 EBITDA Margin % is 19.84% as of Mar. 2026. GuruFocus rates BLLN with a GF Score™ of 13/100. The stock has 5 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, BillionToOne ranks better than 60.59% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. BillionToOne's EBITDA for the
three
months ended in Mar. 2026 was $21.5 Mil. BillionToOne's Revenue for the
three
months ended in Mar. 2026 was $108.4 Mil. Therefore, BillionToOne's EBITDA margin for the quarter that ended in Mar. 2026 was 19.84%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
BillionToOne EBITDA Margin % Related Terms
BillionToOne EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for BillionToOne's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLLN vs SHC, VCYT, RDNT: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, BillionToOne's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BillionToOne EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, BillionToOne's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where BillionToOne's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BillionToOne (BLLN) has a EBITDA Margin % of 19.84% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on BillionToOne and its competitors. According to the industry distribution chart, BillionToOne ranks #80 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 39.4%.
Is BillionToOne's EBITDA Margin % too high?
BillionToOne's current EBITDA Margin % is 19.84%. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.00. BillionToOne's value of 19.84% is 296.8% above this industry median. Based on the distribution chart, BillionToOne ranks #80 out of 203 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, BillionToOne has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does BillionToOne's EBITDA Margin % compare to SHC and VCYT?
According to the Medical Diagnostics & Research industry distribution chart, BillionToOne ranks #80 out of 203 companies for EBITDA Margin %. This puts BillionToOne in the upper half of its industry. The industry median EBITDA Margin % is 5.00. BillionToOne's value of 19.84% is 296.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.00, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BillionToOne's current EBITDA Margin % of 19.84% is 296.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on BillionToOne and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BillionToOne's current EBITDA Margin % is 19.84%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BillionToOne stock overvalued right now?
BillionToOne (BLLN) has a current EBITDA Margin % of 19.84%. The current EBITDA Margin % is 19.84% and 296.8% above the Medical Diagnostics & Research industry median of 5.00. BillionToOne's overall GF Score™ is 13/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For BillionToOne (BLLN), the current EBITDA Margin % is 19.84% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
13GF Score
Get the complete analysis for BLLN
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLLN has been successfully added to your 